Signpath Pharma Competitors and Similar CompaniesClear all
Signpath Pharma's competitors and similar companies include Nektar Therapeutics, Omeros, CureVac and Exelixis.
 Signpath Pharma SignPath Pharma is a biotechnology company that develops products to treat cancer and mitigate drug-induced cardiac arrhythmia. |  Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. | ||||
Founding Date | Founding Date 2006 | Founding Date 1990 | Founding Date 1994 | Founding Date 2000 | Founding Date 1994 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Sandy, US HQ | Locations San Francisco, US HQ Hyderabad, IN Huntsville, US | Locations Seattle, US HQ | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations Alameda, US HQ |
Employees | Employees 11 | Employees 61821% increase | Employees 1968% decrease | Employees 82517% decrease | Employees 1,14712% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 233.8 m | Valuation ($) 248.6 m | Valuation ($) 648.3 m | Valuation ($) 8.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $55.2m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) €535.2m (FY, 2024) | Revenue (est.) $2.3b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods €9.7m (FY, 2024) | Cost of goods $83.7m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit €534.4m (FY, 2024) | Gross profit $2.2b (FY, 2025) |
Net income | Net income N/A | Net income ($164.1m) (FY, 2025) | Net income ($3.4m) (FY, 2025) | Net income €162.2m (FY, 2024) | Net income $782.6m (FY, 2025) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 3 (FY, 2021) | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 5.3m | Total funding raised $ 45m | Total funding raised $ 354.8m | Total funding raised $ 1.1b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Nektar Therapeutics
HQ
San Francisco, US
Employees
618↑ 21% increase
Nektar Therapeutics is a stage-clinical biopharmaceutical company.
View companyOmeros
HQ
Seattle, US
Employees
196↓ 8% decrease
Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers.
View company
CureVac
HQ
Tübingen, DE
Employees
825↓ 17% decrease
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View company
Exelixis
HQ
Alameda, US
Employees
1,147↓ 12% decrease
Exelixis is an oncology company that develops cancer treatments.
View company